<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24346924</article-id>
      <article-id pub-id-type="pmc">3875963</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20132365</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Allogeneic hematopoietic stem cell transplantation in mycosis
fungoides<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Transplante alog&#xEA;nico de c&#xE9;lulas-tronco hematopoi&#xE9;ticas em micose
fungoide</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Atalla</surname>
            <given-names>Angelo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hallack Neto</surname>
            <given-names>Abrah&#xE3;o Elias</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Siqueira</surname>
            <given-names>Denise Bittencourt</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Toledo</surname>
            <given-names>Gabriela Cumani</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> MD, Master's degree in Internal Medicine, Federal University of Rio de
Janeiro (UFRJ) - Head of Unit of Hematology and Bone Marrow Transplantation, University
Hospital from Federal University of Juiz de Fora (HU-UFJF). Associate Professor,
Department of Internal Medicine, UFJF - Juiz de Fora (MG), Brazil.</aff>
      <aff id="aff02"><label>2</label> MD, PhD in Hematology, Universidade de S&#xE3;o Paulo (USP) - Associate
Professor, Medical School, Universidade Federal de Juiz de Fora (UFJF) - Juiz de Fora
(MG), Brazil.</aff>
      <aff id="aff03"><label>3</label> Medicine Student - Hospital Maternidade Therezinha de Jesus, Faculdade
de Ci&#xEA;ncias M&#xE9;dicas e da Sa&#xFA;de de Juiz de Fora (SUPREMA)- Juiz de Fora (MG), Brazil.</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing address: </bold>Angelo Atalla, Rua Catulo Breviglieri s/n&#xBA; - Santa
Catarina, 36036-110 - Juiz de Fora - MG, Brazil. E-mail:
<email>angeloatalla@yahoo.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>6 Suppl 1</issue>
      <fpage>216</fpage>
      <lpage>219</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>12</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>06</day>
          <month>1</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Mycosis Fungoides is typically an indolent disease in early stages. However,
approximately 30% of patients have advanced staged disease at presentation and 20%
will develop it at some time. These patients have a poorer prognosis with a median
survival of 2-4 years. The only curative option for mycosis fungoides may be
hematopoietic allogeneic stem cell transplantation. We report the case of a patient
with mycosis fungoides in an advanced stage (IIB), refractory to treatment options.
She underwent allogeneic hematopoietic stem-cell transplantation (allo-HSCT). The
patient remains in complete remission nineteen months after allo-HSCT. Allogeneic
transplantation can alter the natural history of mycosis fungoides and should be
considered in patients who have refractory disease or short-lived responses with
standard therapies.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>Micose Fungoide &#xE9; tipicamente uma doen&#xE7;a indolente em est&#xE1;gios iniciais. No entanto,
aproximadamente 30% dos pacientes t&#xEA;m doen&#xE7;a avan&#xE7;ada na apresenta&#xE7;&#xE3;o e 20% ir&#xE3;o
desenvolv&#xEA;-la em algum momento. Esses pacientes t&#xEA;m um pior progn&#xF3;stico com uma
sobrevida m&#xE9;dia de dois a quatro anos. A &#xFA;nica possibilidade de cura &#xE9; o transplante
alog&#xEA;nico de c&#xE9;lulas-tronco hematopoi&#xE9;ticas. Relatamos o caso de uma paciente com
micose fungoide em est&#xE1;gio avan&#xE7;ado (IIB), refrat&#xE1;ria &#xE0;s op&#xE7;&#xF5;es terap&#xEA;uticas e que
foi submetida a um transplante alog&#xEA;nico de c&#xE9;lulas-tronco hematopoi&#xE9;ticas. A
paciente permanece em remiss&#xE3;o completa 19 meses ap&#xF3;s o procedimento. O transplante
alog&#xEA;nico &#xE9; capaz de mudar a hist&#xF3;ria natural da micose fungoide e deve ser
considerado em pacientes com doen&#xE7;a avan&#xE7;ada e refrat&#xE1;ria aos tratamentos
dispon&#xED;veis.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Hematopoietic stem cell transplantation</kwd>
        <kwd>Lymphoma, T-Cell, cutaneous</kwd>
        <kwd>mycosis fungoides</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Mycosis fungoides (MF) is the most common subtype of primary cutaneous T-cell lymphomas,
with an annual incidence of 0.36 cases per 100,000 person-years.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r02">2</xref></sup>
MF affects men twice as often as women, is more common in black people, and manifests
with higher incidence over the age of 50.<sup><xref ref-type="bibr" rid="r03">3</xref></sup> The prognosis MF depends on the age and clinical stage of the
patient.<sup><xref ref-type="bibr" rid="r04">4</xref></sup>
</p>
      <p>It is characterized initially by scaly, non-infiltra tive, erythematous or hypopigmented
plaques, persistent, of varying sizes, and featuring intense itching. In the advanced
stages (&gt; or = IIB) it becomes deeply infiltrated, ulcerated, violet staining, with
nodules and tumors appearing that can become infected. Belatedly it can spread to lymph
nodes and visceral organs.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r05">5</xref></sup> Approximately 30% of patients have for
advanced staged disease with generalized erythroderma or tumor at the time of
presentation, and 20% will develop advanced disease.<sup><xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r04">4</xref></sup> The correct diagnosis of
MF can take years because of its similarity to other benign skin conditions. In the USA,
it can take about six years from the time symptoms begin until the diagnosis of MF, and
some patients require multiple biopsies over the years.<sup><xref ref-type="bibr" rid="r01">1</xref></sup>
</p>
      <p>The chronic nature of the disease results in many patients being treated with multiple
therapies, including: PUVA, radiotherapy, corticosteroids, alpha-interferon,
chemotherapy, and immunotherapy.3 Patients with advanced disease have a median survival
of only two to four years; refractory patients are considered incurable with
chemotherapy alone and most of these therapies are palliative.<sup><xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r06">6</xref>,<xref ref-type="bibr" rid="r07">7</xref></sup>
</p>
      <p>There is hope that Hematopoietic Stem Cell Transplants (HSCT) have the potential to
provide prolonged remissions or a possible cure for advanced MF; however, their role is
not well defined.<sup><xref ref-type="bibr" rid="r06">6</xref>-<xref ref-type="bibr" rid="r08">8</xref></sup> We report the case of a female patient with MF, with
approximately 13 years of evolution and subjected to several treatments but obtaining
low response. The advanced stage and the lack of therapeutic options had led to an
indication of allogeneic HSCT (allo-HSCT). The effect of HSCT in the patient's illness
in a follow-up of 19 months is present here. </p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 44-year-old white woman observed an erythema in the sternal region that progressed to
involvement of the whole body in the form of urticarial plaques. The picture remained
stable with topical and systemic steroids for eight years. Progression was observed with
elevated and pruritic patches and plaques with purulent discharge from secondary
infection on an extensive portion of the body surface. </p>
      <p>When the patient came to our service, we performed a skin biopsy with
immunohistochemistry that revealed cutaneous lymphoproliferative disease compatible with
anaplastic large T-cell lymphoma focally CD30+ or Histiocytic sarcoma. Bone marrow
biopsy was normal. CHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine and
prednisone) chemotherapy was initiated, totaling eight cycles, with minimal initial
response in plaques and pruritus, but reappearing at the end of the eighth cycle. A new
skin biopsy showed cutaneous T-cell lymphoma with epidermotropism, CD45+ and CD3+
(suggesting MF). Staged as IIB (T3-N0-M0), with 80% affected area, and presenting the
most advanced lesions in the trunk, breasts and legs. </p>
      <p>Subcutaneous interferon 3,000,000U was initiated, three times a week, gradually
increasing to 12,000,000U and radiotherapy in tougher skin areas in the right groin.
Major improvement of the lesions was obtained with interferon, but this had to be
suspended because of non-hematological toxicity and disease progression. Gemcitabine,
1000mg/m&#xB2; per week, was initiated. There was a significant regression of lesions, but
recurrence was noticed at the end of the sixth cycle. </p>
      <p>Her condition progressively worsened despite partial and temporary improvements with the
various treatment modalities. The patient's skin was diffusely infiltrated (<xref ref-type="fig" rid="f01">Figures 1</xref> and <xref ref-type="fig" rid="f02">2</xref>) with patches, plaques, and tumors. The patient was referred to Euryclides de
Jesus Zerbini Transplants Hospital, in S&#xE3;o Paulo, and a reduced-intensity conditioning
(RIC) allogeneic HLA matched sibling transplant was performed. After conditioning with
fludarabine and melfalan she received peripheral blood stem-cells from her brother.
Graft-versus-host-disease (GVHD) prophylaxis was done with mycophenolate mofetil and
cyclosporine. </p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Mycosis fungoides lesions in breasts</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0216-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Mycosis fungoides lesion in breast extending to the back</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0216-g02"/>
      </fig>
      <p>Engraftment took place on D+11 and the patient was discharged from the hospital on D+14,
with complete remission. Skin biopsy of residual hyperpigmented patches (<xref ref-type="fig" rid="f03">Figure 3</xref>) showed GVHD without evidence of lymphocyte
atypia. The patient has been in complete remission (<xref ref-type="fig" rid="f04">Figures 4</xref> and <xref ref-type="fig" rid="f05">5</xref>) for more than one year
without treatment or any signs of GVHD, and peripheral blood mononuclear cells are 100%
donor. </p>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Graft-versus-host-disease - hyperchromic macules on the back</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0216-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Remission of mycosis fungoides lesions after allogeneic hematopoietic stem cell
transplantation</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0216-g04"/>
      </fig>
      <fig id="f05" orientation="portrait" position="float">
        <label>FIGURE 5</label>
        <caption>
          <p>Remission of mycosis fungoides lesions after allogeneic hematopoietic stem cell
transplantation</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0216-g05"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Advanced MF is associated with a poor outcome. Allo-HSCT has proved to be an effective
therapy in MF, demonstrating a decrease in the relapse rate and an overall increase in
disease-free survival compared with conventional therapy. Allogeneic transplantation
from a healthy donor not only eliminates the potential of graft contamination by tumor
cells but also provides an immunologic antitumor effect, known as graft-versus-lymphoma
(GVL).<sup><xref ref-type="bibr" rid="r08">8</xref>,<xref ref-type="bibr" rid="r09">9</xref></sup> Although only a few patients have been treated with
allo-HSCT until now, the results are consistent and promising.<sup><xref ref-type="bibr" rid="r06">6</xref>,<xref ref-type="bibr" rid="r07">7</xref>,<xref ref-type="bibr" rid="r09">9</xref>,<xref ref-type="bibr" rid="r10">10</xref></sup>
</p>
      <p>In the <italic>Wu et al</italic>. meta-analysis, 70% of patients undergoing allo-HSCT
exhibited GVHD, the majority being mild to moderate, particularly in skin
tissue.<sup><xref ref-type="bibr" rid="r10">10</xref></sup> In the <italic>Molina
et. al </italic>series of transplants, complete remission of skin lesions, tumors and
ulcerated areas, itching and pain was observed in 100% of patients after
allo-HSCT.<sup><xref ref-type="bibr" rid="r08">8</xref></sup> The results of
<italic>Duarte et al. </italic>showed that one year after allo-HSCT, 42% of their
patients remained in remission.<sup><xref ref-type="bibr" rid="r09">9</xref></sup> Our
patient has achieved early remission and is maintaining it for over a year after
transplantation. More than two thirds of patients with advanced stage CTCL, after
receiving an allo-HSCT, were alive and without evidence of disease for more than three
years, which appears to be substantially higher than the median for disease-free
survival, or even the overall rate for such patients.<sup><xref ref-type="bibr" rid="r09">9</xref></sup>
</p>
      <p>Most patients undergoing allo-HSCT previously received an average of seven different
treatments before transplantation, similar to our patient who received five. However,
despite these values, the optimal time for transplantation remains unknown; it is
expected that, in the future, morbidity and the risk of recurrence may be even lower.
Nevertheless, it is unquestionable that the allo-HSCT has a role of great importance in
the management of CTCL, especially MF. The results observed in our patients are
encouraging, and further studies are needed to answer the questions that still
remain.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p> Work perfomed at the University Hospital - Federal University of Juiz de Fora
(HU-UFJF) - Juiz de Fora (MG), Brazil.</p>
      </fn>
      <fn id="fn02" fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn id="fn03" fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES </title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Doorn</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Van Haselen</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>van Voorst Vader</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Geerts</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Heule</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>de Rie</surname>
              <given-names>M</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Mycosis fungoides: disease evolution and prognosis of 309 Dutch
patients</article-title>
          <source>Arch Dermatol</source>
          <year>2000</year>
          <volume>136</volume>
          <fpage>504</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="pmid">10768649</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinstock</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Horn</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>Mycosis fungoides in the United States: increasing incidence and
descriptive epidemiology</article-title>
          <source>JAMA</source>
          <year>1988</year>
          <volume>260</volume>
          <fpage>42</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="pmid">3379722</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whittaker</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Foss</surname>
              <given-names>FM</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and tolerability of currently available therapies for the
mycosis fungoides and Sezary syndrome variants of cutaneous T-cell
lymphoma</article-title>
          <source>Cancer Treat Rev</source>
          <year>2007</year>
          <volume>33</volume>
          <fpage>146</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="pmid">17275192</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Mraz-Gernhard</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Varghese</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hoppe</surname>
              <given-names>RT</given-names>
            </name>
          </person-group>
          <article-title>Long-term outcome of 525 patients with mycosis fungoides and Sezary
syndrome: clinical prognostic risk factors for disease progression</article-title>
          <source>Arch Dermatol</source>
          <year>2003</year>
          <volume>139</volume>
          <fpage>857</fpage>
          <lpage>866</lpage>
          <pub-id pub-id-type="pmid">12873880</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamashita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Abbade</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Marques</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Marques</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Mycosis fungoides and S&#xE9;zary syndrome: clinical, histopathological and
immunohistochemical review and update</article-title>
          <source>An Bras Dermatol</source>
          <year>2012</year>
          <volume>87</volume>
          <fpage>817</fpage>
          <lpage>830</lpage>
          <pub-id pub-id-type="pmid">23197199</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schlaak</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pickenhain</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Theurich</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Skoetz</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>von Bergwelt-Baildon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kurschat</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Allogeneic stem cell transplantation versus conventional therapy for
advanced primary cutaneous T-cell lymphoma</article-title>
          <source>Cochrane Database Syst Rev</source>
          <year>2012</year>
          <volume>1</volume>
          <elocation-id/>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jacobsen</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>VT</given-names>
            </name>
            <name>
              <surname>Cutler</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Koreth</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>DC</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>A large single-center experience with allogeneic stem-cell
transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis
fungoides/Sezary syndrome</article-title>
          <source>Ann Oncol</source>
          <year>2011</year>
          <volume>22</volume>
          <fpage>1608</fpage>
          <lpage>1613</lpage>
          <pub-id pub-id-type="pmid">21252059</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Molina</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zain</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Arber</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Angelopolou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>O'Donnell</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Murata-Collins</surname>
              <given-names>J</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Durable clinical, cytogenetic and molecular remissions after
allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and
mycosis fungoides</article-title>
          <source>J Clin Oncol</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>6163</fpage>
          <lpage>6171</lpage>
          <pub-id pub-id-type="pmid">16135483</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Duarte</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Canals</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Onida</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gabriel</surname>
              <given-names>IH</given-names>
            </name>
            <name>
              <surname>Arranz</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Arcese</surname>
              <given-names>W</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Allogeneic hematopoietic cell transplantation for patients with
mycosis fungoides and S&#xE9;zary syndrome: a retrospective analysis of the Lymphoma
Working Party of the European Group for Blood and Marrow
Transplantation</article-title>
          <source>J Clin Oncol</source>
          <year>2010</year>
          <volume>28</volume>
          <fpage>4492</fpage>
          <lpage>4499</lpage>
          <pub-id pub-id-type="pmid">20697072</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Lavori</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Hoppe</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Stockerl-Goldstein</surname>
              <given-names>KE</given-names>
            </name>
          </person-group>
          <article-title>A meta-analysis of patients receiving allogeneic or autologous
hematopoietic stem cell transplant in mycosis fungoides and S&#xE9;zary
syndrome</article-title>
          <source>Biol Blood Marrow Transplant</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>982</fpage>
          <lpage>990</lpage>
          <pub-id pub-id-type="pmid">19589488</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
